Halozyme Therapeutics, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012. Balance-sheet comparisons are with December 31, 2011. Halozyme is a biopharmaceutical company developing and commercializing enzyme-based therapies and its Enhanze drug-delivery platform. Revenue came mainly from collaborations; Hylenex recombinant was its marketed product, reintroduced in December 2011. The company reported multiple proprietary and partnered programs in development.
Financial performance and position
Amounts below are in millions of dollars except per-share data.
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Total revenue | $7.44 | $7.54 |
| Product sales, net | $0.19 | $0.17 |
| Collaborative-agreement revenue | $7.25 | $7.38 |
| Operating expenses | $22.58 | $17.20 |
| Operating loss | $(15.14) | $(9.66) |
| Net loss | $(15.12) | $(9.64) |
| Basic and diluted loss per share | $(0.14) | $(0.10) |
| Cash used in operating activities | $(19.36) | $(11.09) |
| Cash and cash equivalents at quarter-end | $116.61 | $52.83 at December 31, 2011 |
| Total deferred revenue at quarter-end | $42.62 | $40.88 at December 31, 2011 |
Research and development expense was $15.89 million, up 15% year over year; selling, general and administrative expense was $6.62 million, up 94%. Management attributed the increases principally to compensation and headcount growth, manufacturing activity, and commercial infrastructure and marketing for Hylenex. No debt balance is presented in the supplied balance sheet; reported liabilities consist principally of deferred revenue and operating liabilities. Gross or operating margin was not identified as a key measure in the filing.
Material changes and notable developments
- Revenue was broadly stable, but net loss increased by $5.48 million, primarily as operating expenses grew.
- Operating cash use increased by $8.27 million year over year. Financing provided $83.12 million, including $81.48 million net proceeds from a February public offering of 7.82 million shares at $10.61 per share and $1.65 million from stock-option exercises.
- Cash rose to $116.61 million from $52.83 million at year-end. Common shares outstanding increased to 112.41 million at March 31 from 103.99 million at December 31.
- Q1 collaborative revenue included a $4 million Roche regulatory milestone after Roche submitted a European application for subcutaneous Herceptin. The prior-year quarter included $5 million of Roche clinical milestone revenue.
- Hylenex shipments to wholesalers are deferred until sell-through can be supported and returns and chargebacks can be reliably estimated. Product sales therefore remained limited; management expected them to increase in 2012.
Outlook, risks and contingencies
- Management expected current cash to fund operations for at least the next 12 months and forecast 2012 net cash burn of approximately $55–$60 million. It did not expect revenue to fund operations for several years and noted that additional financing may be needed.
- Management expected R&D expense to increase in 2012 as clinical programs advance, and SG&A and product costs to rise with Hylenex commercialization. Spending and cash needs depend on clinical progress, manufacturing scale-up and collaboration milestones.
- Pipeline and partnership execution remain uncertain. The filing highlights clinical, regulatory, manufacturing, commercialization, reimbursement, intellectual-property and partner-performance risks. Partners may terminate collaborations on 90 days’ notice.
- In April 2012, after quarter-end, the FDA requested additional data to complete review of Baxter’s HyQ biologics license application; the companies expected this to delay the regulatory timeline.
- Hylenex supply continuity was a risk: the Baxter fill-and-finish agreement had an initial term through December 31, 2012, and the company was working toward a new manufacturer. The filing also cites dependence on contract manufacturers for API and manufacturing scale-up.
- The company reported an accumulated deficit of $260.1 million and a history of operating losses and negative cash flow. It cautioned that future financing may not be available on acceptable terms; equity financing could dilute shareholders.
- No legal proceedings were identified whose adverse outcome management considered likely to have a material effect. Management stated disclosure controls were effective at quarter-end and reported no significant changes in internal control over financial reporting.
Key facts for investors to verify
- Cash runway relative to the stated $55–$60 million 2012 net cash-burn forecast, and whether further financing is required.
- Clinical and regulatory progress for proprietary programs, particularly ultrafast insulin, PEGPH20 and HTI-501, and for partnered products.
- HyQ’s revised FDA review timeline and the continuity, capacity and qualification of Hylenex and API manufacturing.
- Hylenex sell-through, returns and chargeback estimates, and whether commercial sales grow as management expected.
- Revenue dependence on collaboration milestones, partner-requested services and partner decisions, including any collaboration changes or terminations.